Drug Profile
Derazantinib - Basilea Pharmaceutica/Merck & Co
Alternative Names: AQ-14741087; ARQ-087; ARQ-087.2HCl; BAL 087; Derazantinib hydrochlorideLatest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator ArQule
- Developer Basilea Pharmaceutica; Institute for Clinical Cancer Research IKF GmbH at Krankenhaus Nordwest; Merck & Co; Peking University; Sinovant Sciences
- Class Amines; Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Fibroblast growth factor receptor antagonists; Macrophage colony stimulating factor receptor antagonists; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cholangiocarcinoma
- Phase I/II Gastric cancer; Urogenital cancer
- Preclinical Breast cancer
- No development reported Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-0 development in Cholangiocarcinoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO, Capsule)
- 28 May 2023 No recent reports of development identified for phase-0 development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (PO)
- 16 Feb 2023 Eli Lilly and Company terminates phase-I/II FIDES-03 trial in Gastric cancer (Combination therapy, Second-line therapy or greater, Recurrent, Late-stage disease, Inoperable/Unresectable) in United Kingdom, Germany, France, Belgium, Italy, USA, Argentina, Australia, Brazil, Chile, South Korea, Poland, Russia, Spain and Turkey (IV, Infusion) due to administrative reasons not related to patient safety (NCT04604132) (EudraCT2019-004505-27)